Prelude Therapeutics (PRLD) Treasury Shares (2019 - 2026)
Prelude Therapeutics (PRLD) posted Treasury Shares of $439080.0 for Q1 2026, up 99.13% sequentially from $220500.0 in Q4 2025, and up 14.08% YoY from $384875.0 in Q1 2025.
Prelude Therapeutics (PRLD) Treasury Shares (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Treasury Shares for 8 years, with the latest figure at $439080.0 in Q1 2026.
- Quarterly Treasury Shares rose 14.08% year-over-year to $439080.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $439080.0 (up 14.08% YoY) and the FY2025 annual result came in at $220500.0, up 292.0% from the prior year.
- Treasury Shares advanced to $439080.0 in Q1 2026 per PRLD's latest filing, from $220500.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $514641.0 in Q1 2022 and troughed at $56250.0 in Q4 2024.
- A 5-year average of $225291.7 and a median of $201716.0 in 2022 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2023 and 2025: Treasury Shares sank 68.18% in 2023, then soared 313.29% in 2025.
- Over 5 years, Treasury Shares stood at $201716.0 in 2022, then sank by 48.57% to $103750.0 in 2023, then plunged by 45.78% to $56250.0 in 2024, then surged by 292.0% to $220500.0 in 2025, then jumped by 99.13% to $439080.0 in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $439080.0, $220500.0, and $292375.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 415,330.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 415,330.00 |
| Jun 30, 2026 | 415,330.00 |
| Mar 31, 2026 | 439,080.00 |
| Mar 31, 2026 | 439,080.00 |
| Dec 31, 2025 | 220,500.00 |
| Dec 31, 2025 | 220,500.00 |
| Sep 30, 2025 | 292,375.00 |
| Sep 30, 2025 | 292,375.00 |
| Jun 30, 2025 | 337,750.00 |
| Jun 30, 2025 | 337,750.00 |
| Mar 31, 2025 | 384,875.00 |
| Mar 31, 2025 | 384,875.00 |
| Dec 31, 2024 | 56,250.00 |
| Dec 31, 2024 | 56,250.00 |
| Sep 30, 2024 | 71,875.00 |
| Sep 30, 2024 | 71,875.00 |
| Jun 30, 2024 | 82,500.00 |
| Jun 30, 2024 | 82,500.00 |
| Mar 31, 2024 | 93,125.00 |
| Mar 31, 2024 | 93,125.00 |